Callan Capital adds Agios Pharmaceuticals Inc (AGIO) to its portfolio

Agios Pharmaceuticals Inc (AGIO) : Callan Capital added new position in Agios Pharmaceuticals Inc during the most recent quarter end. The investment management firm now holds 7,000 shares of Agios Pharmaceuticals Inc which is valued at $327,740 , the company said in a statement filed on May 11, 2016 with the SEC.Agios Pharmaceuticals Inc makes up approximately 0.14% of Callan Capital’s portfolio.

Other Hedge Funds, Including , Landscape Capital Management L.l.c. sold out all of its stake in AGIO during the most recent quarter. The investment firm sold 12,752 shares of AGIO which is valued $597,049.Blackrock Institutional Trust Company N.a. reduced its stake in AGIO by selling 1,629 shares or 0.27% in the most recent quarter. The Hedge Fund company now holds 612,020 shares of AGIO which is valued at $28.7 Million.Tiaa Cref Investment Management reduced its stake in AGIO by selling 100 shares or 0.13% in the most recent quarter. The Hedge Fund company now holds 76,780 shares of AGIO which is valued at $3.3 Million.Diam Ltd. boosted its stake in AGIO in the latest quarter, The investment management firm added 7,215 additional shares and now holds a total of 54,838 shares of Agios Pharmaceuticals Inc which is valued at $2.4 Million. Agios Pharmaceuticals Inc makes up approx 0.03% of Diam Ltd.’s portfolio. Birchview Capital Lp sold out all of its stake in AGIO during the most recent quarter. The investment firm sold 3,400 shares of AGIO which is valued $166,430.

Agios Pharmaceuticals Inc opened for trading at $46.83 and hit $50.82 on the upside on Monday, eventually ending the session at $50.57, with a gain of 8.01% or 3.75 points. The heightened volatility saw the trading volume jump to 7,50,628 shares. Company has a market cap of $1,918 M.

On the company’s financial health, Agios Pharmaceuticals Inc reported $-0.64 EPS for the quarter, beating the analyst consensus estimate by $ 0.29 according to the earnings call on May 5, 2016. Analyst had a consensus of $-0.93. The company had revenue of $31.28 million for the quarter, compared to analysts expectations of $25.66 million. The company’s revenue was down -8.5 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $-0.13 EPS.

Many Wall Street Analysts have commented on Agios Pharmaceuticals Inc. Company shares were Reiterated by SunTrust on May 18, 2016 to “Buy”, Firm has raised the Price Target to $ 65 from a previous price target of $57 .Company shares were Reiterated by Sun Trust Rbsn Humphrey on May 18, 2016 to “Buy”, Firm has raised the Price Target to $ 65 from a previous price target of $57 .Sun Trust Rbsn Humphrey Initiated Agios Pharmaceuticals Inc on Mar 30, 2016 to “Buy”, Price Target of the shares are set at $57.

Agios Pharmaceuticals Inc. (Agios) is a biopharmaceutical company. The Company is engaged in the discovery and development of orally available small molecule medicines for the treatment of cancer and rare genetic disorders (RGDs) of metabolism using cellular metabolism as a platform. It is also engaged in the identification and validation of altered metabolic pathways within abnormal cells. Its products include AG-221 AG-120 and AG-348. Its lead product AG-348 in the RGD program is an orally available small molecule that targets pyruvate kinase-R for the treatment of pyruvate kinase deficiency. AG-221 is potent inhibitor of the mutated IDH2 protein being developed for the treatment hematological malignancies and advanced solid tumors. AG-120 is an orally available selective potent inhibitor of the mutated IDH1 protein being developed for the treatment hematological malignancies and advanced solid tumors.

Leave a Reply

Agios Pharmaceuticals Inc - Is it time to Sell?

Top Brokerage Firms are advising their investors on Agios Pharmaceuticals Inc. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.